Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03343028 · ClinicalTrials.gov registry record

Biomarker Establishment for Superior Treatment of PTSD

A clinical trial, sponsored by Stanford University.

Completed
Registry status
292
Enrollment target

NCT03343028: Completed study, sponsored by Stanford University.

NCT03343028 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 292 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03343028 has completed, sponsored by Stanford University.

COMPLETED
Registry status
292 participants
Enrollment target

Study Summary

The purpose of Biomarker Establishment for Superior Treatment of PTSD is to accelerate research on the discovery of biological, neurological and neuroimaging markers for Post- Traumatic Stress Disorder (PTSD). The investigators hope to validate and extend the network efficiency and verbal memory biomarker for PTSD. The investigators hope to learn whether there are pretreatment biological factors that can predict response to therapy. They want to do this by understanding the brain network function, relating EEG to functional magnetic resonance imaging, and application of network analysis tool.

Interventions

  • OTHER Psychotherapy

Trial Details

FieldValue
Enrollment Target 292 participants
Start Date 2016-09
Est. Completion 2019-09-30

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT03343028

The ClinicalTrials.gov registry entry for NCT03343028 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Psychotherapy is the first listed.

NCT03343028 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03343028 about?

NCT03343028 is a clinical study titled "Biomarker Establishment for Superior Treatment of PTSD". The purpose of Biomarker Establishment for Superior Treatment of PTSD is to accelerate research on the discovery of biological, neurological and neuroimaging markers for Post- Traumatic Stress Disorder (PTSD). The investigators hope to validate and extend the network efficiency and verbal memory bio...

What is the current status of trial NCT03343028?

This trial is currently completed. The enrollment target is 292 participants. The study started on 2016-09. Estimated completion is 2019-09-30.

What interventions are being tested in trial NCT03343028?

The interventions under investigation include: Psychotherapy (OTHER).

Who is sponsoring clinical trial NCT03343028?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.